Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Genmab A/S stands eighth on our list and has recently opened new sites in the US.

Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse and UniBody, the corporation has historically partnered with major pharmaceutical companies such as Johnson & Johnson and AbbVie to bring its innovations to market. However, the company is now undergoing a strategic transformation to become a fully integrated global commercial entity.

In June 2025, Genmab A/S (NASDAQ:GMAB) opened a major new U.S. site in Plainsboro, New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. This move gives the company greater control over its innovation, regulatory processes, and patient outreach, aligning with a broader biotech industry trend toward independence and vertical integration.

The business’s oncology portfolio continues to gain traction. Tivdak (cervical cancer) received full FDA approval in April 2024, while Epkinly (lymphoma), which earned accelerated approval in 2023, has shown strong sales growth in the U.S. Genmab A/S (NASDAQ:GMAB)’s pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. At the June 2025 ASCO meeting, the company presented promising Rina-S data, supporting an upcoming Phase III trial.

The corporation continues to benefit from its successful collaboration with Johnson & Johnson on DARZALEX, which remains a significant revenue driver. The company is also focused on long-term growth by investing in talent retention through stock-based incentives.

While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.